

Yair Molad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7482809/publications.pdf>

Version: 2024-02-01

33
papers

1,041
citations

471061

17
h-index

454577

30
g-index

36
all docs

36
docs citations

36
times ranked

1270
citing authors

#	ARTICLE	IF	CITATIONS
1	Update on colchicine and its mechanism of action. <i>Current Rheumatology Reports</i> , 2002, 4, 252-256.	2.1	169
2	Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1993, 36, 1111-1120.	6.7	168
3	Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. <i>Arthritis and Rheumatism</i> , 2004, 50, 173-182.	6.7	135
4	Recurrent aphthous stomatitis in Behçet's disease: clinical features and correlation with systemic disease expression and severity. <i>Journal of Oral Pathology and Medicine</i> , 1999, 28, 193-196.	1.4	71
5	Intravascular Neutrophil Activation in Systemic Lupus Erythematosus (SLE): Dissociation between Increased Expression of CD11b/CD18 and Diminished Expression of L-Selectin on Neutrophils from Patients with Active SLE. <i>Clinical Immunology and Immunopathology</i> , 1994, 71, 281-286.	2.1	46
6	Renal outcome and vascular morbidity in systemic lupus erythematosus (SLE): Lack of association with the angiotensin-converting enzyme gene polymorphism. <i>Seminars in Arthritis and Rheumatism</i> , 2000, 30, 132-137.	1.6	42
7	Association of Low Serum Complement C3 with Reduced Patient and Renal Survival in Antimyeloperoxidase-Associated Small-Vessel Vasculitis. <i>Nephron Clinical Practice</i> , 2014, 126, 67-74.	2.3	34
8	Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study. <i>Clinical Rheumatology</i> , 2014, 33, 649-657.	1.0	32
9	Hemophagocytosis by small cell lung carcinoma. <i>American Journal of Hematology</i> , 1991, 36, 154-156.	2.0	31
10	Serum Soluble Triggering Receptor on Myeloid Cells-1 (sTREM-1) is Elevated in Systemic Lupus Erythematosus but does not Distinguish Between Lupus Alone and Concurrent Infection. <i>Inflammation</i> , 2013, 36, 1519-1524.	1.7	31
11	The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13268.	1.7	31
12	Connective tissue disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 119, 463-473.	1.0	29
13	Adult-onset Still's disease following mRNA COVID-19 vaccination. <i>Clinical Immunology</i> , 2021, 233, 108878.	1.4	25
14	Heart valve calcification in young patients with systemic lupus erythematosus: A window to premature atherosclerotic vascular morbidity and a risk factor for all-cause mortality. <i>Atherosclerosis</i> , 2006, 185, 406-412.	0.4	24
15	Hematological Manifestations among Patients with Rheumatic Diseases. <i>Acta Haematologica</i> , 2021, 144, 403-412.	0.7	21
16	Controlled Ovarian Hyperstimulation: A State of Neutrophil Activation. <i>American Journal of Reproductive Immunology</i> , 1999, 42, 288-291.	1.2	20
17	CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and shedding. <i>Innate Immunity</i> , 2013, 19, 623-630.	1.1	18
18	Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. <i>Lupus Science and Medicine</i> , 2022, 9, e000651.	1.1	18

#	ARTICLE	IF	CITATIONS
19	Soluble triggering receptor expressed on myeloid cells-1 is a biomarker of anti-CCP-positive, early rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2015, 45, 557-564.	1.7	17
20	Systemic lupus erythematosus and pregnancy. <i>Current Opinion in Obstetrics and Gynecology</i> , 2006, 18, 613-617.	0.9	16
21	The safety of pulse corticosteroid therapy- Systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 534-545.	1.6	12
22	Elevated plasma level of soluble triggering receptor expressed on myeloid cells-1 is associated with inflammation activity and is a potential biomarker of thrombosis in primary antiphospholipid syndrome. <i>Arthritis Research and Therapy</i> , 2019, 21, 10.	1.6	11
23	Incident gout and chronic Kidney Disease: healthcare utilization and survival. <i>BMC Rheumatology</i> , 2019, 3, 11.	0.6	9
24	Neutrophil Adhesion Molecule Expression in Familial Mediterranean Fever: Discordance between the Intravascular Regulation of β 2 Integrin and L-Selectin Expression in Acute Attack. <i>Journal of Investigative Medicine</i> , 2004, 52, 58-61.	0.7	8
25	Lower socioeconomic status worsens outcome of patients with systemic lupus erythematosus independently of access to healthcare. <i>Lupus</i> , 2022, 31, 532-540.	0.8	8
26	Corneal melting in rheumatoid arthritis patients treated with a tectonic reinforcing corneolimb graft: an interventional case series. <i>International Ophthalmology</i> , 2018, 38, 1317-1324.	0.6	5
27	Elevated Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Level in Patients with Acute Coronary Syndrome (ACS): A Biomarker of Disease Severity and Outcome. <i>Mediators of Inflammation</i> , 2021, 2021, 1-9.	1.4	3
28	Anti-Ro/SS-A antibody is associated with worse pulmonary outcome and reduced overall survival in systemic sclerosis. <i>Modern Rheumatology</i> , 2022, 32, 1086-1093.	0.9	3
29	Guanine polynucleotides are self-antigens for human natural autoantibodies and are significantly reduced in the human genome. <i>Immunology</i> , 2015, 146, 401-410.	2.0	2
30	Diffused coronary involvement in Takayasu arteritis with concomitant malignancy. <i>Clinical Rheumatology</i> , 2022, 41, 921-928.	1.0	2
31	Constitutively increased neutrophil surface expression of beta2-integrin in Yemenite Jews. <i>Inflammation</i> , 2003, 27, 301-305.	1.7	0
32	Response to the letter to the editor by Gkougkourelas et al. <i>EJC</i> 2017; 47: e12850. <i>European Journal of Clinical Investigation</i> , 2017, 47, e12850.	1.7	0
33	Anti-CD20 Monoclonal Antibody (Rituximab) as an Optional Treatment for Intractable Acquired Glanzmann's Thrombasthenia. <i>Blood</i> , 2006, 108, 3971-3971.	0.6	0